Insulin-Like Growth Factor-I and Breast Cancer Therapy

Author:

Ibrahim Yasir H.1,Yee Douglas1

Affiliation:

1. University of Minnesota Cancer Center, Minneapolis, Minnesota

Abstract

Abstract Targeting hormonal and growth factor signaling pathways has proven to be useful in the treatment of breast cancer. In vitro, animal, and epidemiologic evidence provide a rationale for the relevance of the insulin-like growth factor (IGF) system to breast cancer biology. The IGF system has been implicated in promoting mitogenic, metastatic, and antiapoptotic phenotypes in breast cancer. As a consequence of the ability of IGF to promote tumorigenesis, pharmacologic interventions targeting the IGF system are being devised. Such strategies include decreasing ligand production, ligand binding, or receptor activation. In this article, directed anti-IGF strategies and the possible clinical impact of using such therapies for treating breast cancer are discussed.

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Reference80 articles.

1. Salomon W, Daughaday W. A hormonally controlled serum factor which stimulates sulfate incorporation by cartilage in vitro. J Lab Clin Med 1957;49:825–36.

2. Laron Z, Pertzelan A, Mannheimer S. Genetic pituitary dwarfism with high serum concentration of growth hormone—a new inborn error of metabolism? Isr J Med Sci 1966;2:152–5.

3. Yu H, Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 2000;92:1472–89.

4. Werner H, Woloschack M, Stannard B, Shen-Orr Z, Roberts C, LeRoith D. The insulin-like growth factor receptor: molecular biology, heterogeneity, and regulation. In: LeRoith D, editor. Insulin-like growth factors: molecular and cellular aspects. Boca Raton: CRC Press; 1991. p.18–48.

5. Baserga R. The IGF-IR receptor in normal and abnormal growth. In: Hormones and growth factors in development and neoplasia. New York: Wiley-Liss; 1998. p. 269–87.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3